

US Small Cap Equity Strategy

December 31, 2021

Objective

The US Small Cap Equity Strategy seeks long term compounding by focusing its investments in smaller capitalization companies of US markets.

Why Invest

- Clearly defined, transparent, and consistent process
- Driven by fundamentals, supported by evidence
- Active risk management with disciplined portfolio construction
- Advancing positive change through active engagement

Portfolio Managers

David Kim, CFA

Lead Portfolio Manager
24 years of experience

Matthew Franco, CFA

Co-Portfolio Manager
26 years of experience

Annualized Returns (%)

As of 12/31/21



*Past performance is not indicative of future results, and the principal value and investment return will fluctuate, so that you may have a gain or loss when you sell your units.

Strategy Facts

Inception

September 1, 2006

Firm Assets

\$19.5B*

Strategy Assets

\$372M*

Benchmark

Russell 2000 Growth

Vehicles

Separate account, commingled fund, CIT** and UCITS

Top 10 Holdings

As of 12/31/21

Security	Country	Sector	% of Portfolio	% of Index
Nova	US	IT	3.8	0.0
WillScot Mobile	US	Industrials	3.7	0.6
Exponent	US	Industrials	3.7	0.4
Omniceil	US	Health Care	3.6	0.5
Wyndham Hotels	US	Consumer	3.6	0.0
Helios	US	Industrials	3.4	0.2
AMN Healthcare	US	Health Care	3.3	0.4
Repligen	US	Health Care	3.2	0.0
Novanta	US	IT	3.2	0.4
United Community Banks	US	Financials	3.1	0.0

*Assets include Assets Under Management (\$18.6B) & Assets Under Advisement (\$0.9B). Index: Russell 2000 Growth

**SEI Trust Company (the "Trustee") serves as the Trustee of the Trust and maintains ultimate fiduciary authority over the management of, and the investments made in, the Fund. The Fund is part of a Collective Investment Trust (the "Trust") operated by the Trustee. The Trustee is a trust company organized under the laws of the Commonwealth of Pennsylvania and a wholly owned subsidiary of SEI Investments Company (SEI). Axiom CIT Trusts are trusts for the collective investment of assets of participating tax qualified pension and profit sharing plans and related trusts, and governmental plans as more fully described in the Declaration of Trust. As bank collective trusts, the Axiom CIT Trusts are exempt from registration as an investment company. Axiom CIT Trusts are managed by SEI Trust Company, the trustee, based on the investment advice of Axiom Investors, LLC, the investment adviser to the trusts

Source: Factset and Axiom. There can be no assurance that the Strategy will continue to hold these positions or that weightings do not change after the as of date stated. Please refer to the attached GIPS compliant presentation for complete performance information.


Risk/Return Analysis & Portfolio Characteristics (%)

As of 12/31/21


5 Year Statistics	Axiom	Index
Cumulative Return (%)	188.4	97.1
Annualized Return (%)	23.6	14.5
Annualized Excess Return (%)	9.1	-
Batting Average (% Quarterly)	65.0	-
Annualized Standard Deviation (%)	17.0	20.5
Tracking Error (%)	8.4	-
Information Ratio	1.1	-
Annualized Sortino Ratio	2.2	1.0
Upside Capture (% Quarterly)	112.6	-
Downside Capture (% Quarterly)	62.4	-

	Axiom	Index
Holdings	50	1246
% in Axiom Top 10 Holdings	34.5%	2.6%
Wgt. Avg. Market Cap (\$B)	\$5.9	\$4.0
Median Market Cap (\$B)	\$4.9	\$1.2
Liquidity (\$M/Day)	\$44	\$40
Net Debt/Equity Ratio	29.2	34.5
Price Earnings Ratio	28.0	19.9
Earnings Growth Rate	16.5	23.2
PEG Ratio (PE/Growth Rate)	1.7	0.9
Wgt. Avg. Carbon Intensity	47.1	72.5

Sector Exposure (%)



Sector Allocation vs. Index (%)



Index: Russell 2000 Growth

Currency: USD, Risk/return statistics are gross of fees.

Past performance is no guarantee of future results. Source: Factset and Axiom.

There can be no assurance that the Strategy will continue to hold these positions or that weightings do not change after the as of date stated.

Investing Ahead of the Curve



Commentary

During the fourth quarter 2021, the Axiom US Small Cap Equity Strategy ("Strategy") outperformed the Russell 2000 Growth Index ("Index") net of fees. The Strategy has outperformed the Index on a net of fees basis over the 1-year, 3-year, 5-year, 10-year, and since inception periods.

US small cap growth companies continued to exhibit the prevailing year-to-date trends of price volatility and style rotation driven by the ongoing Coronavirus pandemic, changing inflation and monetary policy expectations, and concerns over moderating economic growth. Macroeconomic data reflected a peak in growth rates, decreased impact of monetary/fiscal policy, and tougher comparisons. US Real GDP forecasts for 2021 were revised down by -30 basis points and by -40 basis points for 2022. Higher, more persistent inflation data was reported while ongoing global supply chain issues remain a key risk. The Federal Reserve began the tapering of its bond-buying program and expectations of up to 3 future interest rate hikes moved into calendar year 2022. Vaccination volumes continued to improve, consumer balance sheets remain in strong shape, and employment data strengthened, supporting further reopening of the economy, but the emergence and rapid spread of the delta and more recently omicron Covid variants led to renewed public health concerns and economic growth uncertainties. As a result, rotations between value/cyclical companies and growth/defensive companies continued with the Russell 2000 Growth Index ending relatively unchanged for the fourth quarter.

Six out of the 11 GICS sectors were positive contributors to relative performance in the fourth quarter. The best performing sector on a relative basis was health care, led by leading pharmaceutical automation solutions vendor Omnicell, biopharmaceutical manufacturer United Therapeutics, and an underweight position in biotechnology and pharmaceutical companies. Other top contributing sectors included consumer discretionary, driven by specialty retailer Boot Barn, and materials, driven by sustainable packaging producer Ranpak Holdings. The largest detracting sectors for the quarter included information technology, where companies faced headwinds from premium valuations and more difficult comparisons in 2022, as well as consumer staples and real

estate, due to the relative underweight position.

From an individual stock perspective, the best relative contributors for the quarter were Nova Ltd., WillScot Mobile Mini Holdings, Boot Barn Holdings, Helios Technologies, and Ranpak Holdings. These companies reported better than expected fundamental performance with dynamic growth and margin expansion opportunities in 2022. The largest detracting stocks were Heska Corporation – veterinary and animal health diagnostic products, TaskUs Inc.- customer care/business process outsourcing organization, Sprout Social- social media engagement software provider, Varonis Systems- security software platform developer, and Genius Sports - data, technology and services partner to the sports betting industry. These companies reported solid fundamental results but were negatively impacted by higher interest rates and premium valuations, while facing more difficult comparables, rising input / labor costs, and global supply chain disruptions into 2022.

Axiom continues to invest in dynamic growth stocks delivering superior growth and profitability. Covid trends, vaccine and booster distribution, the pace of economic growth, fiscal/monetary policy actions, and geopolitical risks will continue to result in periods of elevated volatility and uncertainty in equity markets. While we continue to closely monitor these events, our focus remains on fundamental, bottom-up investing in innovative, higher quality small cap companies that are visibly and dynamically growing their revenues and earnings faster than prevailing economic growth rates. Well-capitalized, profitable, and reasonably valued growth companies that are executing in the current environment remain a differentiated and compelling area of investment.

The information presented is not definitive investment advice, should not be relied on as such, and should not be viewed as a recommendation by Axiom. The securities presented are not representative of all of the securities purchased, sold or held for advisory clients, and it should not be assumed that investment in the securities identified was or will be profitable.

Client Partnership Contacts

Lindsay Chamberlain

Managing Director
203.422.8039
lchamberlain@axiom-investors.com

Greg Schneider

Senior Vice President
203.422.8038
gschneider@axiom-investors.com

Steve Hanson

Vice President
203.422.8085
shanson@axiom-investors.com

Megan Strater

Vice President
203.422.8041
mstrater@axiom-investors.com

Matthew Welling, CFA

Vice President
203.422.8044
mwelling@axiom-investors.com

Investing Ahead of the Curve



Footnotes and Disclaimers

	Composite return (gross of fees)	Composite return (net of fees)	Benchmark Total Return (%)	No. of accounts	Market value (millions)	Total firm assets (millions)	% of firm assets (%)	Internal dispersion (%)	Composite 3-year standard deviation (%)	Benchmark 3-year standard deviation (%)
2021	25.61%	24.58%	2.83%	≤5	283.9	18,639.7	1.52	N/A	17.06	23.07
2020	48.98%	47.77%	34.63%	≤5	242.7	18,535.9	1.31	N/A	20.74	25.10
2019	30.87%	29.80%	28.48%	≤5	204.3	13,458.1	1.52	N/A	15.67	16.37
2018	-2.70%	-3.51%	-9.31%	≤5	208.0	9,729.2	2.14	N/A	15.73	16.46
2017	21.02%	20.04%	22.17%	≤5	363.1	12,116.0	3.00	N/A	12.56	14.59
2016	5.52%	4.68%	11.32%	≤5	282.4	9,671.6	2.92	N/A	14.23	16.67
2015	-2.73%	-3.50%	-1.38%	≤5	44.2	8,704.3	0.51	N/A	14.37	14.95
2014	1.11%	0.31%	5.60%	≤5	101.7	9,482.3	1.07	N/A	13.14	13.82
2013	54.36%	53.17%	43.30%	≤5	103.7	9,949.8	1.04	N/A	14.65	17.27
2012	10.26%	9.47%	14.59%	≤5	78.0	8,611.6	0.91	N/A	17.68	20.72
2011	5.82%	4.91%	-2.91%	≤5	1.9	10,161.2	0.02	N/A	20.31	24.31

Fee schedule: First \$10 million: 0.80%; next \$15 million: 0.75%; Balance: 0.70%

Firm Compliance Statement: Axiom Investors LLC (the "Firm") claims compliance with the Global Investment Performance Standards (GIPS®) and has prepared and presented this report in compliance with the GIPS standards. Axiom has been independently verified for the period September 1, 1998 to September 30, 2021. A firm that claims compliance with the GIPS standards must establish policies and procedures for complying with all the applicable requirements of the GIPS standards. Verification provides assurance on whether the firm's policies and procedures related to composite and pooled fund maintenance, as well as the calculation, presentation, and distribution of performance, have been designed in compliance with the GIPS standards and have been implemented on a firm-wide basis. The Axiom US Small Cap Equity - IPO Eligible composite has had a performance examination for the periods September 1, 2006 to September 30, 2021. The verification and performance examination reports are available upon request.

Definition of the Firm: The firm is currently defined for GIPS purposes as Axiom International Investors, LLC (the "Firm") is a registered investment advisor under the Investment Act of 1940. Policies: Policies for valuing investments, calculating performance, and preparing GIPS Reports are available upon request. Past performance does not predict or guarantee future results.

Composite Description: The US Small Cap Equity - IPO Eligible strategy (the "Composite") is designed for investors who seek to invest in a broadly diversified portfolio of small cap equities. Portfolios are invested in smaller capitalization equity and equity-related securities in companies located within the United States. Currencies may be actively managed to reduce portfolio volatility. The Composite represents the performance of all Institutional small cap style fee-paying, discretionary equity accounts, regardless of asset size and comingled fund(s) that are eligible to invest in Initial Public Offerings. The Composite was initiated and created in September 2006. A list of composite descriptions, a list of limited distribution pooled fund descriptions, a list of broad distribution pooled funds and performance results are available upon request.

Benchmark Description: The benchmark is the Russell 2000 Growth index, which is designed to measure the performance of the small cap growth segment of the U.S. equity universe. The benchmark is calculated on a total return basis and is free float-adjusted market cap weighted and unmanaged.

Significant Cash Flow Policy: Accounts with a cash flow greater than 20% of the portfolio market value are excluded for the month.

Reporting Currency: Valuations are computed and performance is reported in U.S. dollars.

Fees: Gross of fees returns are presented before management and custodial fees but after all trading expenses. Net of fees returns are calculated by deducting the highest fee from the monthly gross composite return which is expressed above in the stated fee schedule. Returns include the reinvestment of income. The fee schedule for the Axiom U.S. Small Cap Equity Portfolio, which is included in the US Small Cap Equity Composite - IPO Eligible is listed above. The total expense ratio as of December 31, 2020 was 0.61%. The Axiom U.S. Small Cap Equity Trust CIT, which is also included in the composite has an all-in fee (management fees & expenses) of 0.70%. Internal Dispersion: Internal dispersion is calculated using the asset-weighted standard deviation of annual gross returns of those portfolios that were in the composite for the entire year. If 5 or less accounts, N/A is shown.

Annualized Standard Deviation: The three-year annualized standard deviation measures the variability of the composite gross returns and the benchmark returns over the preceding 36-month period. The standard deviation is not required for periods prior to 2011. GIPS® is a registered trademark of CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein.

This may contain forward-looking statements within the meaning of the federal securities laws. Actual results could and likely will differ, sometimes materially, from those projected or anticipated.

We are not undertaking any obligation to update or revise any forward looking statements whether as a result of new information, future events or otherwise. You should not take any statements regarding past trends as a representation that trends or activities will continue in the future. Accordingly, you should not put undue reliance on these statements.

The information contained herein represents neither an offer to sell nor a solicitation of an offer to buy any securities or investment service. This strategy will only be offered through appropriate documents, copies of which may be obtained upon request from ClientRelations@axiom-investors.com. Offers will not be made in any jurisdiction in which the making of an offer or the acceptance thereof would not be in compliance with the laws of such jurisdiction. Investors should read applicable materials carefully before making a decision to invest.

Risks of investing in the strategy:

Potential loss of investment: No guarantee or representation is made that the investment program used by Axiom will be successful. The strategy represents a speculative investment and involves a high degree of risk. An investment in the strategy should be discretionary capital set aside strictly for speculative purposes. Investors must have the financial ability, sophistication/experience and willingness to bear the risks of an investment in the strategy. An investment in the strategy is not suitable for all investors. An investor could lose or a substantial portion of his/her/its investment. Only qualified eligible investors may invest in the strategy. Because of the nature of the trading activities, the results of the strategy's operations may be volatile from month to month and from period to period. Accordingly, investors should understand that past performance is not indicative of future results.

Fees and expenses: The strategy may be subject to substantial charges for management, advisory and brokerage fees. It may be necessary for those accounts that are subject to these charges to make substantial trading profits to avoid depletion or exhaustion of their assets.

Reliance on key persons: The strategy's manager or advisor has total trading authority over the strategy and may be subject to various conflicts of interest. The death, disability or departure of the manager or advisor may have a material effect on the strategy.

Counterparty and bankruptcy risk: Although Axiom will attempt to limit its transactions to counterparties which are established, well-capitalized and creditworthy, the strategy will be subject to the risk of the inability of counterparties to perform with respect to transactions, whether due to insolvency, bankruptcy or other causes, which could subject the strategy to substantial losses.

Volatile markets: Market prices are difficult to predict and are influenced by many factors, including: changes in interest rates, weather conditions, government intervention and changes in national and international political and economic events.

The above summary is not a complete list of the risks, tax considerations and other important disclosures relating to Axiom products or services. Prospective clients should read all disclosure documents provided by Axiom relating to its products or services before engaging Axiom's advisory services.

The information herein is only current as of the date indicated, and may be superseded by subsequent market events or for other reasons.

The Axiom Investors Collective Investment Trust is a trust for the collective investment of assets of participating tax-qualified pension and profit sharing plans and related trusts, and governmental plans as more fully described in the Declaration of Trust. The Axiom Investors Trust is managed by SEI Trust Company, the trustee, based on the investment advice of Axiom Investors, the investment adviser to the trust. As a bank collective trust, the Axiom Investors Trust is exempt from registration as an investment company.